Share Email Print

Proceedings Paper

1.5T MRI-guided trans-perineal laser ablation of locally recurrent prostate adenocarcinoma
Author(s): E. Frederick McPhail; Lance A. Mynderse; Matthew R. Callstrom; Krzysztof R. Gorny; Roger J. McNichols; Thomas D. Atwell; Matthew T. Gettman; Kimberly K. Amrami; Akira Kawashima; David A. Woodrum
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Introduction: Biochemical recurrence of prostate cancer after definitive therapy with radical prostatectomy (RP) is known to occur between 25-30%. We present the first known case of 1.5T MRI guided ablation using laser interstitial thermal therapy (LITT) for locally recurrent prostate cancer following RP. Methods: The patient elected to undergo MRI-guided LITT of the biopsy proven cancer recurrence using an FDAapproved MRI compatible, 980nm, 15-watt laser system with MR thermometry. Under T2-weighted MR(1.5T Siemens) imaging, guidance and targeting of the lesions with trans-perineal placement of laser applicators. Multiple cycles of laser energy were used to ablate the tumor. A MRI-compatible urethral cooling catheter was placed to prevent urethral thermal damage. Results: Intra-procedural temperature mapping allowed continuous monitoring of the ablation zone and permitted ablation control until tumor coverage was achieved. Additionally, the protective cooling effects of the urethral cooling catheter could also be seen with the temperature mapping. Post-ablation gadolinium and T2 weighted MR imaging demonstrated an ablation defect encompassing the recurrent tumor with no residual hyper-enhancing nodules. Three month follow-up shows no residual or recurrent tumor seen on MR imaging. Conclusion: This represents the first known, successful, MRI-guided, LITT procedures at 1.5T for locally recurrent prostate adenocarcinoma following RP.

Paper Details

Date Published: 2 March 2010
PDF: 15 pages
Proc. SPIE 7548, Photonic Therapeutics and Diagnostics VI, 754816 (2 March 2010); doi: 10.1117/12.844992
Show Author Affiliations
E. Frederick McPhail, Mayo Clinic (United States)
Lance A. Mynderse, Mayo Clinic (United States)
Matthew R. Callstrom, Mayo Clinic (United States)
Krzysztof R. Gorny, Mayo Clinic (United States)
Roger J. McNichols, Visualase, Inc. (United States)
Thomas D. Atwell, Mayo Clinic (United States)
Matthew T. Gettman, Mayo Clinic (United States)
Kimberly K. Amrami, Mayo Clinic (United States)
Akira Kawashima, Mayo Clinic (United States)
David A. Woodrum, Mayo Clinic (United States)

Published in SPIE Proceedings Vol. 7548:
Photonic Therapeutics and Diagnostics VI
Anita Mahadevan-Jansen; Andreas Mandelis; Brian Jet-Fei Wong M.D.; Nikiforos Kollias; Henry Hirschberg M.D.; Kenton W. Gregory M.D.; Reza S. Malek; E. Duco Jansen; Guillermo J. Tearney; Steen J. Madsen; Bernard Choi; Justus F. R. Ilgner; Haishan Zeng; Laura Marcu, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?